Erratum to: Survival, safety, and prognostic factors for outcome with Regorafenib in patients with metastatic colorectal cancer refractory to standard therapies: results from a multicenter study (REBECCA) nested within a compassionate use program

from Cancer via ola Kala on Inoreader http://ift.tt/2aFsZUT
via IFTTT